Compare Novo Nordisk A/S (NVO) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Novo Nordisk A/S trades at $45.87 (market cap $207.31B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $29. The key difference: Novo Nordisk A/S pays a 3.76% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals.
| NVO | RDTE | |
|---|---|---|
Market Cap | $207.31B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $34.20 |
52-Week Low | $35.29 | $26.40 |
Enterprise Value | $222.02B | — |
Dividend Yield | 3.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RDTE trades at $28.91, up 1.19% today, but technical indicators signal a bearish trend with moving averages showing significant sell pressure. The stock exhibits a consistent dividend distribution pattern, with multiple payments scheduled through mid-2026. Recent news coverage highlights the ETF's high-yield strategy but raises concerns about structural risks and capital erosion potential.
The outlook remains cautious due to the bearish technical structure and fundamental concerns about the covered-call strategy's sustainability. Investment opportunity exists for income-focused investors attracted to the dividend yield, but risks include capped upside participation and potential NAV deterioration during market rallies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
